Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

341. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden Lindgren P, Stenestrand U, Malmberg K, Jonsson B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined percutaneous coronary intervention (PCI) with clopidogrel plus aspirin versus aspirin alone in patients with unstable coronary artery disease (CAD). Type of intervention Treatment. Economic study type Cost-effectiveness

NHS Economic Evaluation Database.2005

342. Analysis of aspirin-associated risks in healthy individuals

Analysis of aspirin-associated risks in healthy individuals Analysis of aspirin-associated risks in healthy individuals Analysis of aspirin-associated risks in healthy individuals Hur C, Simon L S, Gazelle G S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The study examined the use aspirin 325 mg daily in healthy individuals. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of healthy individuals of 50 years of age. Setting The setting was primary care. The economic study was carried out in the USA. Dates to which data relate The effectiveness data and some resource use data were derived from studies published

NHS Economic Evaluation Database.2005

343. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone Schleinitz M D, Heidenreich P A Record (...) (75 mg/day) plus aspirin (325 mg/day). Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients with unstable angina or non-Q wave MI. The patients included in the analysis were suffering from an ACS characterised by electrocardiographic changes or elevated serum cardiac markers in association with chest pain. Patients who had prolonged ST-segment elevation, or who had undergone

NHS Economic Evaluation Database.2005

344. A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin

A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin Article Text Clinical prediction guide A prediction rule identified patients with atrial fibrillation at low risk of stroke while taking aspirin Free Graeme J Hankey , MBBS, MD, FRCP Statistics

Evidence-Based Medicine (Requires free registration)2005

345. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. 15659723 2005 01 20 2005 01 27 2014 11 20 1533-4406 352 3 2005 Jan 20 The New England journal of medicine N. Engl. J. Med. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. 238-44 Concurrent therapy with a proton-pump inhibitor is a standard treatment for patients receiving aspirin who are at risk for ulcer. Current U.S. guidelines also recommend clopidrogel for patients who have (...) major gastrointestinal intolerance of aspirin. We compared clopidogrel with aspirin plus esomeprazole for the prevention of recurrent bleeding from ulcers in high-risk patients. We studied patients who took aspirin to prevent vascular diseases and who presented with ulcer bleeding. After the ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either 75 mg of clopidogrel daily plus esomeprazole placebo twice daily or 80 mg of aspirin daily plus 20 mg

NEJM2005

346. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. 15998890 2005 07 06 2005 07 12 2016 11 24 1538-3598 294 1 2005 Jul 06 JAMA JAMA Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. 47-55 Basic research and observational evidence as well as results from trials of colon polyp recurrence suggest a role for aspirin in the chemoprevention of cancer. To examine the effect (...) of aspirin on the risk of cancer among healthy women. In the Women's Health Study, a randomized 2 x 2 factorial trial of aspirin and vitamin E conducted between September 1992 and March 2004, 39 876 US women aged at least 45 years and initially without previous history of cancer, cardiovascular disease, or other major chronic illness were randomly assigned to receive either aspirin or aspirin placebo and followed up for an average of 10.1 years. A dose of 100 mg of aspirin (n=19 934) or aspirin placebo

JAMA2005

347. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. 15758000 2005 03 24 2005 03 31 2014 11 20 1533-4406 352 12 2005 Mar 24 The New England journal of medicine N. Engl. J. Med. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. 1179-89 A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate (...) reperfusion or reocclusion of the infarct-related artery, leading to an increased risk of complications and death. We enrolled 3491 patients, 18 to 75 years of age, who presented within 12 hours after the onset of an ST-elevation myocardial infarction and randomly assigned them to receive clopidogrel (300-mg loading dose, followed by 75 mg once daily) or placebo. Patients received a fibrinolytic agent, aspirin, and when appropriate, heparin (dispensed according to body weight) and were scheduled

NEJM2005

348. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. 15753114 2005 03 31 2005 04 05 2013 11 21 1533-4406 352 13 2005 Mar 31 The New England journal of medicine N. Engl. J. Med. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. 1293-304 Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke (...) . There are few similar data in women. We randomly assigned 39,876 initially healthy women 45 years of age or older to receive 100 mg of aspirin on alternate days or placebo and then monitored them for 10 years for a first major cardiovascular event (i.e., nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes). During follow-up, 477 major cardiovascular events were confirmed in the aspirin group, as compared with 522 in the placebo group, for a nonsignificant reduction

NEJM2005

349. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.

Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. 15800226 2005 03 31 2005 04 05 2014 11 20 1533-4406 352 13 2005 Mar 31 The New England journal of medicine N. Engl. J. Med. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. 1305-16 Atherosclerotic intracranial arterial stenosis is an important cause of stroke. Warfarin is commonly used in preference to aspirin for this disorder, but these therapies have not been compared (...) in a randomized trial. We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target international normalized ratio, 2.0 to 3.0) or aspirin (1300 mg per day) in a double-blind, multicenter clinical trial. The primary end point was ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke. After 569 patients had undergone randomization, enrollment

NEJM2005

350. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. 16271642 2005 11 07 2005 12 01 2015 06 16 1474-547X 366 9497 2005 Nov 05 Lancet (London, England) Lancet Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. 1607-21 Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high (...) . The antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary syndromes without ST-segment elevation, but its effects in patients with ST-elevation MI were unclear. 45,852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly allocated clopidogrel 75 mg daily (n=22,961) or matching placebo (n=22,891) in addition to aspirin 162 mg daily. 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to continue until

Lancet2005

351. Aspirin sensitivity: implications for patients with coronary artery disease.

Aspirin sensitivity: implications for patients with coronary artery disease. CONTEXT: Although acetylsalicylic acid (aspirin) is commonly used for patients with chronic cardiovascular disease, a minority of patients have a sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs. OBJECTIVE: To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary (...) artery disease (CAD). EVIDENCE ACQUISITION: Published articles were identified through a search of MEDLINE and the Cochrane databases using the dates 1966 to June 2004 and the search terms aspirin allergy, coronary artery disease, aspirin desensitization, and aspirin sensitivity. References of retrieved articles were also reviewed for pertinent studies. Articles were included in this review if they were controlled studies, published in the English language, and appeared in a peer-reviewed journal. EVIDENCE

JAMA2004

352. Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer

Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Article Text Therapeutics Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Free James E Shaw , MD, MPH Statistics from Altmetric.com No Altmetric data available for this article. ( 2003 ) N Engl J Med 348 , 883

Evidence-Based Medicine (Requires free registration)2004

353. Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk

Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Article Text Therapeutics Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Free James E Shaw , MD, MPH Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2004

354. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page

NIHR HTA programme2004

355. Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose

Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose BestBets: Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose Report By: Stewart Teece - Clinical Research Fellow Search checked by Ian Crawford - Clinical Research Fellow Institution: Manchester Royal Infirmary Current web editor: Simon Carley - Consultant in Emergency Medicine Date Submitted: 1st March 2000 Date (...) Completed: 2nd September 2004 Last Modified: 5th October 2004 Status: Green (complete) Three Part Question [In overdose with aspirin or other non steroidals] is [gastric lavage better than charcoal or nothing] at [reducing toxicity]? Clinical Scenario A 53 year old widow attends the emergency department having taken 20 aspirin and 20 ibuprofen one and a half hours previously. You remember that non-steroidals slow gastric emptying and wonder whether gastric lavage would be of use in toxicity reduction

BestBETS2004

356. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. 15276392 2004 07 27 2004 08 19 2015 06 16 1474-547X 364 9431 2004 Jul 24-30 Lancet (London, England) Lancet Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled (...) trial. 331-7 Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo

Lancet2004

357. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk.

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. CONTEXT: Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer. NSAIDs inhibit cyclooxygenase activity and thereby reduce prostaglandin synthesis; prostaglandins stimulate aromatase gene expression and thereby stimulate estrogen biosynthesis. Given the importance of estrogen (...) in the pathogenesis of breast cancer, the ability of aspirin and other NSAIDs to protect against breast cancer could vary according to hormone receptor status. OBJECTIVES: To determine the association between the frequency and duration of use of aspirin and other NSAIDs and breast cancer risk and to investigate whether any observed association is more pronounced for women with hormone receptor-positive breast cancers. DESIGN, SETTING, AND PATIENTS: Population-based case-control study of women with breast cancer

JAMA2004

358. A prospective study of aspirin use and the risk for colorectal adenoma.

A prospective study of aspirin use and the risk for colorectal adenoma. BACKGROUND: Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma. However, the effect of dose and duration of use, particularly in an average-risk population, is not well understood. OBJECTIVE: To examine the influence of dose and duration of aspirin use in the primary prevention of colorectal adenoma. DESIGN: Prospective cohort study (...) . SETTING: Nurses' Health Study. PARTICIPANTS: 27 077 women, 34 to 77 years of age, without a history of adenoma, cancer, inflammatory bowel disease, or familial polyposis, who underwent lower endoscopy between 1980 and 1998. MEASUREMENTS: 1368 cases of confirmed distal colorectal adenoma were diagnosed between 1980 and 1998. Self-reported data on aspirin use were collected from biennial questionnaires. RESULTS: After other risk factors for adenoma were adjusted, women who regularly used aspirin (>

Annals of Internal Medicine2004

359. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) coronary syndromes: a systematic review and economic evaluation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R CRD summary This review found that clopidogrel in combination with standard therapy was significantly more effective than aspirin alone for the treatment of acute coronary syndromes. Overall, this was a well-conducted review and the authors' conclusions are supported by the evidence presented. Authors' objectives To review the clinical

DARE.2004

360. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice Jenkins C, Costello J, Hodge L CRD summary This review assessed the prevalence of aspirin-induced asthma in the general asthma population, and cross-sensitivity to paracetamol and non-prescription (...) non-steroidal anti-inflammatories. The authors' main conclusion was that aspirin-induced asthma in adults is more prevalent than previously suggested. Limitations in the review methodology and reporting mean that it is not possible to comment on the reliability of this conclusion. Authors' objectives To assess the prevalence of aspirin-induced asthma in the general asthma population, and the cross-sensitivity of these individuals to other commonly used non-prescription analgesics. Searching

DARE.2004